DUBLIN--(BUSINESS WIRE)--The "Global Respiratory Partnering 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
The Global Respiratory Partnering 2012-2018: Deal trends, players and financials report provides an understanding and access to the Respiratory partnering deals and agreements entered into by the worlds leading healthcare companies.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Respiratory disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Respiratory deals.
The report presents financial deal terms values for Respiratory deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
Report scope
- Trends in Respiratory dealmaking in the biopharma industry since 2012
- Analysis of Respiratory deal structure
- Access to headline, upfront, milestone and royalty data
- The leading Respiratory deals by value since 2012
Available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Respiratory dealmaking
Chapter 3 - Financial deal terms for Respiratory partnering
Chapter 4 - Leading Respiratory deals and dealmakers
Chapter 5 - Respiratory contract document directory
Chapter 6 - Respiratory dealmaking by therapeutic target
